Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
-$0.25 today
- Market cap
- $630.80M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
Volume 0.98M
Average 1.02M
JANX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Janux Therapeutics, Inc.NASDAQ: JANX
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$35M, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was -$35M.
Context
- Accounts receivables amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Accounts receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$35M or moves back toward the trailing-twelve-month quarterly average of -$8.75M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 8M | — |
Accounts Receivables vs competitors
How JANX compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +401.4% is the 2nd highest of 7, against a peer median of +7.6%.
- Accounts receivables amounts to 161.9% of revenue for JANX, versus a peer median of 3.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $125.44M USD | +174128.2% | — | 9.2% | |
| LTM Mar 2026 | $35M USD | +401.4% | — | 161.9% | |
| LTM Mar 2026 | €1.5M EUR | +138.9% | -18.5% | 4.0% | |
| LTM Mar 2026 | $1.31M USD | -88.3% | — | 3.7% | |
| LTM Mar 2026 | $1.08M USD | -93.9% | -4.6% | 1.1% | |
| LTM Sep 2026 | $265K USD | -134.8% | +95.9% | 236.6% | |
| LTM Mar 2026 | $117K USD | +103.5% | -41.7% | 0.1% | |
| LTM Sep 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding JANX) | — | +7.6% | -11.5% | 3.8% | |
Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Depreciation & Amortization | 113K | 841K | 1.96M | 2.06M | 2.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.91M | 17.2M | 20.01M | 33.02M | 40.22M |
| Change in Working Capital | 8.84M | 4.28M | (6.55M) | 685K | 6.71M |
| Accounts Receivables | 8M | 0 | 0 | 0 | 0 |
| Inventory | 831K | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.14M | (294K) | 277K | 1.58M | 977K |
| Other Working Capital | (2.13M) | 4.57M | (6.83M) | (899K) | 5.74M |
| Other Non-Cash Items | (169K) | (2.18M) | (7.69M) | (10.59M) | (17.57M) |
| Operating Cash Flow | (16.98M) | (42.92M) | (50.58M) | (43.81M) | (82.24M) |
| Capital Expenditures | (1.48M) | (6.45M) | (1.85M) | (359K) | (1.04M) |
| Acquisitions (Net) | 339.48M | (64.71M) | 0 | 0 | 0 |
| Purchases of Investments | (473.63M) | (294.39M) | (317.34M) | (470.58M) | (705.22M) |
| Sales of Investments | 134.15M | 359.1M | 278M | 212.92M | 405.28M |
| Other Investing Activities | (339.48M) | 64.71M | 0 | 0 | 0 |
| Investing Cash Flow | (340.96M) | 58.27M | (41.19M) | (258.02M) | (300.98M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 204.17M | 500K | 56.53M | 698.27M | 5.29M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (347K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.81M | 0 | 3.02M | 14.97M | 0 |
| Financing Cash Flow | 386.52M | 500K | 59.55M | 713.24M | 4.95M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 28.59M | 15.84M | (32.22M) | 411.4M | (378.27M) |
| Free Cash Flow | (18.46M) | (49.37M) | (52.43M) | (44.17M) | (83.28M) |
Janux Therapeutics, Inc.
NASDAQ:JANX
Intrinsic Alpha fair value
Locked
Current Price
$10.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.